About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015

News

Shanghai, April 20th, 2026 — Luye Pharma Group today announced that the first subject has been enrolled in a U.S. pharmacokinetic (PK) bridging clinical trial of its new molecular entity LY03015. This is the world’s first ...

April 20,2026

Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s Disease-related ...

Shanghai, April 15th, 2026 — Luye Pharma Group today announced that the first subject has been enrolled in a Phase Ⅱ clinical trial in China to evaluate its LY03017 for the treatment of Alzheimer’s Disease-related Psychosis (ADP). ...

April 15,2026

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company